Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke

Bart M. Demaerschalk, Dawn O. Kleindorfer, Opeolu M. Adeoye, Andrew M. Demchuk, Jennifer E. Fugate, James C. Grotta, Alexander A. Khalessi, Elad I. Levy, Yuko Y. Palesch, Shyam Prabhakaran, Gustavo Saposnik, Jeffrey L. Saver (+1 others)
2015 Stroke  
Purpose-To critically review and evaluate the science behind individual eligibility criteria (indication/inclusion and contraindications/exclusion criteria) for intravenous recombinant tissue-type plasminogen activator (alteplase) treatment in acute ischemic stroke. This will allow us to better inform stroke providers of quantitative and qualitative risks associated with alteplase administration under selected commonly and uncommonly encountered clinical circumstances and to identify future
more » ... arch priorities concerning these eligibility criteria, which could potentially expand the safe and judicious use of alteplase and improve outcomes after stroke. Methods-Writing group members were nominated by the committee chair on the basis of their previous work in relevant topic areas and were approved
doi:10.1161/str.0000000000000086 pmid:26696642 fatcat:inrpwrwpg5fqlcy3qvqtne7hra